Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 May;29(5):883–886. doi: 10.1128/aac.29.5.883

Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.

F Rogerie, D Ott, J Vandepitte, L Verbist, P Lemmens, I Habiyaremye
PMCID: PMC284172  PMID: 3524434

Abstract

A severe epidemic of dysentery began late in 1979 in northeast Zaire and spread to Rwanda, Burundi, and Tanzania. The epidemic strain is a multiply resistant Shigella dysenteriae type 1, which acquired resistance against trimethoprim and more recently against nalidixic acid in the course of the epidemic. A comparative open trial in Rwandan adults with Shiga dysentery involved 18 patients treated with norfloxacin at 400 mg twice daily and 12 patients treated with nalidixic acid at 1 g three times daily for 5 days. All isolates showed in vitro susceptibility to both drugs. Though norfloxacin eliminated Shigella organisms from stools more rapidly than nalidixic acid, its clinical superiority did not reach the level of significance. Norfloxacin is a promising drug and is more effective than nalidixic acid in the treatment of multiresistant shigellosis.

Full text

PDF
883

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bannatyne R. M., Toma S., Cheung R. Nalidixic acid analogues and Shigella. Lancet. 1984 Jul 21;2(8395):172–173. doi: 10.1016/s0140-6736(84)91094-8. [DOI] [PubMed] [Google Scholar]
  2. Bennish M., Eusof A., Kay B., Wierzba T. Multiresistant Shigella infections in Bangladesh. Lancet. 1985 Aug 24;2(8452):441–441. doi: 10.1016/s0140-6736(85)92756-4. [DOI] [PubMed] [Google Scholar]
  3. Bogaerts J., Bosmans E., Vandenbulcke L., Lemmens P., Lepage P., Vandepitte J., Ghysels G. Shigella and Salmonella species from Kigali (Rwanda) (1976-1982). Ann Soc Belg Med Trop. 1985 Sep;65(3):281–292. [PubMed] [Google Scholar]
  4. Bose R., Nashipuri J. N., Sen P. K., Datta P., Bhattacharya S. K., Datta D., Sen D., Bhattacharya M. K. Epidemic of dysentery in West Bengal: clinicians' enigma. Lancet. 1984 Nov 17;2(8412):1160–1160. doi: 10.1016/s0140-6736(84)91600-3. [DOI] [PubMed] [Google Scholar]
  5. Carlson J. R., Thornton S. A., DuPont H. L., West A. H., Mathewson J. J. Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens. Antimicrob Agents Chemother. 1983 Oct;24(4):509–513. doi: 10.1128/aac.24.4.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Corrado M. L., Cherubin C. E., Shulman M. The comparative activity of norfloxacin with other antimicrobial agents against Gram-positive and Gram-negative bacteria. J Antimicrob Chemother. 1983 Apr;11(4):369–376. doi: 10.1093/jac/11.4.369. [DOI] [PubMed] [Google Scholar]
  7. Ebright J. R., Moore E. C., Sanborn W. R., Schaberg D., Kyle J., Ishida K. Epidemic Shiga bacillus dysentery in Central Africa. Am J Trop Med Hyg. 1984 Nov;33(6):1192–1197. doi: 10.4269/ajtmh.1984.33.1192. [DOI] [PubMed] [Google Scholar]
  8. Frost J. A., Rowe B., Vandepitte J. Acquisition of trimethoprim resistance in epidemic strain of Shigella dysenteriae type 1 from Zaire. Lancet. 1982 Apr 24;1(8278):963–963. doi: 10.1016/s0140-6736(82)91960-2. [DOI] [PubMed] [Google Scholar]
  9. Frost J. A., Rowe B., Vandepitte J., Threlfall E. J. Plasmid characterisation in the investigation of an epidemic caused by multiply resistant Shigella dysenteriae type 1 in Central Africa. Lancet. 1981 Nov 14;2(8255):1074–1076. doi: 10.1016/s0140-6736(81)91277-0. [DOI] [PubMed] [Google Scholar]
  10. Frost J. A., Willshaw G. A., Barclay E. A., Rowe B., Lemmens P., Vandepitte J. Plasmid characterization of drug-resistant Shigella dysenteriae 1 from an epidemic in Central Africa. J Hyg (Lond) 1985 Apr;94(2):163–172. doi: 10.1017/s0022172400061362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goossens H., De Mol P., Coignau H., Levy J., Grados O., Ghysels G., Innocent H., Butzler J. P. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother. 1985 Mar;27(3):388–392. doi: 10.1128/aac.27.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gross R. J., Threlfall E. J., Ward L. R., Rowe B. Drug resistance in Shigella dysenteriae, S flexneri and S boydii in England and Wales: increasing incidence of resistance to trimethoprim. Br Med J (Clin Res Ed) 1984 Mar 10;288(6419):784–786. doi: 10.1136/bmj.288.6419.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Haltalin K. C., Nelson J. D., Kusmiesz H. T. Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch Dis Child. 1973 Apr;48(4):305–312. doi: 10.1136/adc.48.4.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hansson H. B., Barkenius G., Cronberg S., Juhlin I. Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis. Scand J Infect Dis. 1981;13(3):191–193. doi: 10.3109/inf.1981.13.issue-3.06. [DOI] [PubMed] [Google Scholar]
  15. Lewis M. J. Multiple transmissible drug resistance in an outbreak of Shigella flexneri infection. Lancet. 1967 Nov 4;2(7523):953–956. doi: 10.1016/s0140-6736(67)90793-3. [DOI] [PubMed] [Google Scholar]
  16. Malengreau M., Molima-Kaba, Gillieaux M., de Feyter M., Kyele-Duibone, Mukolo-Ndjolo Outbreak of Shigella dysentery in Eastern Zaire, 1980-1982. Ann Soc Belg Med Trop. 1983 Mar;63(1):59–67. [PubMed] [Google Scholar]
  17. Malengreau M. Nalidixic acid in Shigella dysenteriae outbreaks. Lancet. 1984 Jul 21;2(8395):172–172. doi: 10.1016/s0140-6736(84)91093-6. [DOI] [PubMed] [Google Scholar]
  18. McCormack J. G. Nalidixic acid for shigellosis. Lancet. 1983 Nov 5;2(8358):1091–1091. doi: 10.1016/s0140-6736(83)91081-4. [DOI] [PubMed] [Google Scholar]
  19. Mhalu F. S., Moshi W. K., Mbaga I. A bacillary dysentery epidemic in Dar es Salaam, Tanzania. J Diarrhoeal Dis Res. 1984 Dec;2(4):217–222. [PubMed] [Google Scholar]
  20. Moorhead P. J., Parry H. E. Treatment of sonne dysentery. Br Med J. 1965 Oct 16;2(5467):913–915. doi: 10.1136/bmj.2.5467.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Panhotra B. R., Desai B. Resistant Shigella dysenteriae. Lancet. 1983 Dec 17;2(8364):1420–1420. doi: 10.1016/s0140-6736(83)90947-9. [DOI] [PubMed] [Google Scholar]
  22. Panhotra B. R., Desai B., Sharma P. L. Nalidixic-acid-resistant Shigella dysenteriae I. Lancet. 1985 Mar 30;1(8431):763–763. doi: 10.1016/s0140-6736(85)91310-8. [DOI] [PubMed] [Google Scholar]
  23. Parry H. E. Nalidixic acid for shigellosis. Lancet. 1983 Nov 19;2(8360):1206–1206. doi: 10.1016/s0140-6736(83)91261-8. [DOI] [PubMed] [Google Scholar]
  24. Shungu D. L., Weinberg E., Gadebusch H. H. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother. 1983 Jan;23(1):86–90. doi: 10.1128/aac.23.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES